Brought to you by 
Vifor gets exclusive rights to Isotechnika's voclosporin for lupus and nephrology indications
15 May 2012
Executive Summary
Isotechnika Inc. (immunomodulating therapies) has granted Vifor Pharma Ltd., the drug business of Galenica Group, exclusive worldwide rights to its lead compound voclosporin for lupus and all proteinuric nephrology indications. The license specifically includes the US, but excludes territories already held by Paladin (Canada, South Africa, and Israel), and 3SBio (China, Taiwan, and Hong Kong).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vifor gets exclusive rights to Isotechnika's voclosporin for lupus and nephrology indications
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice